Bellevue Group’s Veracyte VCYT Stock Holding History

Bellevue Group’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,600	Closed	-$143K	–	167
2024 Q4	$143K	Hold	3,600	–	–	﹤0.01%	150
2024 Q3	$123K	Buy	+3,600	New	+$101K	﹤0.01%	154

Other funds holding VCYT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Bellevue Group's VCYT Position: Q1 2025 in Review

Bellevue Group sold out of Veracyte (VCYT) in Q1 2025, closing a stake of 3,600 shares — an estimated $143K sold.

Bellevue Group first reported a position in VCYT in Q3 2024 and held it in 2 quarters. The position peaked at $143K in Q4 2024. 287 funds tracked by Wall St. Rank hold VCYT as of Q1 2025.

Bellevue Group reported no remaining Veracyte position as of Q1 2025 after selling out during the quarter.
Bellevue Group sold 3,600 Veracyte shares in Q1 2025, an estimated $143K.
Bellevue Group first reported a position in Veracyte in Q3 2024 and held it in 2 quarters.
Bellevue Group's Veracyte position peaked at $143K in Q4 2024.
287 funds tracked by Wall St. Rank held Veracyte as of Q1 2025.

Based on Bellevue Group's 13F filing for Q1 2025, filed 14 May 2025.